^
Association details:
Biomarker:IDH2 mutation
Cancer:Anaplastic Astrocytoma
Regimen:PCV (lomustine + Matulane (procarbazine hydrochloride) + vincristine)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Radiotherapy-PCV versus radiotherapy-temozolomide for IDH-mutant anaplastic astrocytoma: a retrospective multicentre analysis of the French POLA cohort

Published date:
02/01/2021
Excerpt:
The 4-year PFS in the RT + PCV arm was 70.8% vs 53.5% in the RT + TMZ arm...RT + PCV significantly improved PFS compared to RT + TMZ for IDH-mutant AA.
DOI:
10.1002/onco.13701